Search results
Results from the WOW.Com Content Network
Last year, GSK had said that the Haleon spin-off and subsequent stake sales would allow the company to sharpen its focus on vaccines and infectious diseases and fund deals to bolster a lacklustre ...
Haleon was established on 18 July 2022 as a corporate spin-off from GSK. [6] Sir Dave Lewis is chairman, with Brian McNamara as CEO. [7] Haleon is listed on the London Stock Exchange and is a component of the FTSE 100, with a secondary listing on the New York Stock Exchange. Annual sales amounted to around £10 billion across 120 markets in ...
GSK sold around 385 million shares at 324 pence apiece, amounting to a 4.2% stake in Haleon. The company was formed in a merger of GSK and Pfizer's consumer healthcare businesses in 2019. The sale ...
British drugmaker GSK spun off its consumer health business on Monday in the biggest listing in Europe for more than a decade, but the unit's market value of 30.5 billion pounds fell well short of ...
Pfizer Inc. (NYSE: PFE) intends to sell its 32% investment in Haleon, a consumer health joint venture with GSK plc (NYSE: GSK), after the business is spun out as an independent listed company in ...
Sensodyne became a part of Haleon, a British multinational consumer healthcare corporation, in July 2022, following the establishment of Haleon as a separate entity through a corporate spin-off from GSK.
On 22 February 2022, GSK announced that the spin-off consumer healthcare company will be called Haleon. [ 76 ] [ 77 ] In January 2022, the company announced that they had received three unsolicited offers from Unilever to acquire the Consumer Healthcare business unit, with the final proposal valuing the business unit at £50 billion (£41.7 ...
Shares in Haleon, which owns brands such as Sensodyne toothpaste and Panadol pain relief, started trading at 330p. GSK consumer spin-off Haleon floats in biggest London listing in a decade Skip to ...